Ritonavir-d6

Ritonavir-d6 is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1][2].

Product Specifications

CAS Number

[1616968-73-0]

Product Name Alternative

ABT 538-d6; RTV-d6

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; HIV; HIV Protease; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Purity

98.84

Solubility

10 mM in DMSO|DMF : ≥ 15mg/mL|DMSO : ≥ 15mg/mL|Ethanol : ≥ 5mg/mL

Smiles

O[C@@H](C[C@H](CC1=CC=CC=C1)NC([C@@H](NC(N(CC2=CSC(C(C([2H])([2H])[2H])C([2H])([2H])[2H])=N2)C)=O)C(C)C)=O)[C@H](CC3=CC=CC=C3)NC(OCC4=CN=CS4)=O

Molecular Formula

C37H42D6N6O5S2

Molecular Weight

726.98

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Eagling VA, et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997 Aug;44 (2) :190-4.|[3]Kumar GN, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277 (1) :423-31.|[4]Weichold FF, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2 (5) :261-9.|[5]Drewe J, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57 (10) :1147-52.|[6]Kumar GN, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27 (8) :902-8.|[7]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.